RUBRACA lowered the risk of cancer progressing or death by 50%1

Men who took RUBRACA were able to go about twice as long without their cancer getting worse compared with men who received a different treatment selected by their doctor (called “physician’s choice”)1*

Results are from 405 patients with advanced prostate cancer, of which 302 had a BRCA1/2 gene mutation. Patients were treated with RUBRACA or physician’s choice* after previous treatment with any androgen receptor pathway inhibitor and did not receive chemotherapy previously.

Eleven point two MONTHS
Eleven point two MONTHS

RUBRACA: A median duration of 

11.2 months before the cancer showed signs of growth, called radiographic progression-free survival (rPFS)

Six point four MONTHS
Six point four MONTHS

Physician’s choice: A median duration of 6.4 months before the cancer grew (rPFS)

*Physician’s choice included a type of chemotherapy (docetaxel) or a second-generation androgen receptor pathway inhibitor (ARPI) (abiraterone or enzalutamide).

RUBRACA is the ONLY PARPi inhibitor proven to be more effective than chemotherapy in men with advanced prostate cancer and a BRCA mutation1,2

Men taking RUBRACA went longer without their cancer getting worse compared to those receiving docetaxel2

Eleven point two MONTHS
Eleven point two MONTHS
RUBRACA: A median duration of
11.2 months before the cancer showed signs of growth (rPFS)
Eight point three MONTHS
Eight point three MONTHS

Docetaxel: A median duration of
8.3 months before the cancer grew (rPFS)

RUBRACA lowered the risk of cancer getting worse or death by 47% compared to chemotherapy2

RUBRACA helped men go longer without their cancer getting worse compared to those on ARPIs2

Eleven point two MONTHS
Eleven point two MONTHS
RUBRACA: A median duration of
11.2 months before the cancer showed signs of growth (rPFS)
Four point five MONTHS
Four point five MONTHS
Second-generation ARPI (abiraterone or enzalutamide): A median duration of
4.5 months before the cancer grew (rPFS)
In the study, most men who started on chemotherapy or hormone therapy later switched to RUBRACA when their cancer worsened3

In a separate study, men who had already received chemotherapy saw a reduction in disease1,4

Results are from 81 patients who had BRCA-mutated advanced prostate cancer and were treated with RUBRACA after previous treatment with
any androgen receptor-directed therapy and a taxane-based chemotherapy4

Forty-six percent
Forty-six percent

of patients achieved a reduction in disease, called an objective response rate4

Fifteen point five MONTHS
Fifteen point five MONTHS

was the median length of time the cancer responded to treatment, also known as the median duration of response4

Sixty-seven percent
Sixty-seven percent
of patients saw at least a 30% decrease in tumor size4

LEARN ABOUT THE SIDE EFFECTS ASSOCIATED WITH RUBRACA

learn more
BRCA, BReast CAncer gene; rPFS, radiographic progression-free survival.
REFERENCES: 1. RUBRACA (rucaparib). Prescribing Information. pharmaand GmbH. 2025. 2. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732. 3. Bryce AH, McDermott RS, Piulats J, et al. Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety. J Clin Oncol. 2025;43:155-155. 4. Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur Urol. 2023;84:321-330.
Tap for safety information

IMPORTANT SAFETY INFORMATION

What is RUBRACA® (rucaparib) used for?

RUBRACA tablets are a prescription medicine used in adults for:

  • The treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
    • That has spread to other parts of the body (metastatic), and
    • Has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.
  • Your healthcare provider will perform a test to make sure RUBRACA is right for you.

It is not known if RUBRACA is safe and effective in children.

What Warnings should you know about RUBRACA?

RUBRACA tablets may cause serious side effects including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with RUBRACA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with RUBRACA. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with RUBRACA, but can be a sign of serious problems, including MDS or AML.

Before you take RUBRACA, tell your healthcare provider about all of your medical conditions, including if you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of RUBRACA. Do not donate sperm during use and for 3 months after the last dose of RUBRACA.

What other important information should I know about RUBRACA?

Your healthcare provider will do blood tests before and every month during treatment with RUBRACA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with RUBRACA until your blood cell counts improve.

Avoid spending time in sunlight while on RUBRACA since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of RUBRACA?

The most common side effects of RUBRACA in people with prostate cancer include: tiredness or weakness, muscle and joint pain, nausea, decrease in hemoglobin (anemia), decreased appetite, changes in liver and kidney function tests, constipation, diarrhea, vomiting, low blood cell counts, shortness of breath, swelling in your legs and feet, dizziness, decreased weight, stomach area (abdominal) pain, changes in how food tastes, rash, tingling sensation and numbness, cough, headache, urinary tract infection, bleeding, photosensitivity reaction.

These are not all the possible side effects of RUBRACA. Call your healthcare provider for medical advice about side effects.

What other medications might interact with RUBRACA?

RUBRACA can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to pharma& at 1-800-506-8501.

  • This information is not comprehensive.
    • How to get more information:
      • Talk to your health care provider or pharmacist.
      • Visit www.rubracaprostate.com to obtain the FDA-approved product labeling.

Please see full Prescribing Information for RUBRACA.

FPO

YOU ARE NOW LEAVING RubracaProstate.com

Are you sure you want to leave?

Continue
Cancel and stay
Skip to content
Rubraca
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.